论文部分内容阅读
目的分析厄贝沙坦治疗轻中度原发性高血压的临床效果。方法将医院2013年6月-2014年6月收治的轻中度原发性高血压患者138例随机分为对照组和观察组各69例,对照组给予卡托普利进行治疗,观察组给予厄贝沙坦进行治疗,对比2组患者治疗效果。结果观察组总有效率为92.75%明显高于对照组的63.77%,不良反应发生率分别为4.34%及23.19%,差异均有统计学意义(P<0.05)。24h动态血压监测结果显示观察组患者收缩压及舒张压下降幅度显著高于对照组,差异有统计学意义(P<0.05)。结论厄贝沙坦治疗轻中度原发性高血压效果确切,安全性好,值得临床推广。
Objective To analyze the clinical efficacy of irbesartan in the treatment of mild to moderate essential hypertension. Methods A total of 138 patients with mild to moderate essential hypertension admitted from June 2013 to June 2014 in our hospital were randomly divided into control group and observation group, with 69 cases in each group. Patients in control group were treated with captopril, while those in observation group Irbesartan treatment, compared with two groups of patients with treatment. Results The total effective rate in the observation group was 92.75%, significantly higher than 63.77% in the control group. The incidence of adverse reactions were 4.34% and 23.19%, respectively, with statistical significance (P <0.05). 24h ambulatory blood pressure monitoring showed that patients in observation group systolic blood pressure and diastolic blood pressure decreased significantly higher than the control group, the difference was statistically significant (P <0.05). Conclusion Irbesartan in the treatment of mild to moderate essential hypertension is effective, safe and worthy of clinical promotion.